Hydrochlorothiazide(DCT) antibody and antigen (hapten, BSA/OVA conjugated)

Diagnostic anti-Hydrochlorothiazide (DCT) antibodies (anti-Hydrochlorothiazide, anti-DCT) and diagnostic hapten-carrier conjugates BSA-Hydrochlorothiazide (DCT), OVA-Hydrochlorothiazide (DCT), KLH-Hydrochlorothiazide (DCT) antigens for Cardiovascular disease DCT detection in ELISA test, competitive ELISA, Lateral flow immunoassay (LFIA), CLIA, TINIA and POCT.

Target products collectionGo to Cardiovascular disease diagnostics products collection>>


Product information

Catalog No.DescriptionUS $ Price (per mg)
GMP-SMT-207-Ag01BSA-Hydrochlorothiazide(DCT)$756.00
GMP-SMT-207-Ag02OVA-Hydrochlorothiazide(DCT)$756.00
GMP-SMT-207-Ab01Anti-human Hydrochlorothiazide(DCT) mouse monoclonal antibody (mAb)$1953.00
GMP-SMT-207-Ab02Anti-human Hydrochlorothiazide(DCT) human monoclonal antibody (mAb)$1953.00

Size: 1mg | 10mg | 100mg



Product Description

BSA-Hydrochlorothiazide(DCT)

Cat No.GMP-SMT-207-Ag01
Product NameBSA-Hydrochlorothiazide(DCT)
TargetHydrochlorothiazide(DCT)
Expression platformSynthetic
Bioactivity validationHydrochlorothiazide(DCT) antibodies binding, Immunogen in Sandwich Elisa, lateral-flow tests, and other immunoassays as control material in DCT level test of Cardiovascular disease (high blood pressure) and related syndrome evaluation
Products descriptionCompetitive immunoassay-validated hapten-carrier conjugates BSA-Hydrochlorothiazide(DCT) / OVA-Hydrochlorothiazide(DCT) is Synthetic.
PurityHigh (TBD)
ApplicationCompetitive immunoassay validation (Competitive ELISA), ELISA, Lateral flow immunoassay (LFIA),colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA),turbidimetric inhibition immuno assay (TINIA) and Immunonephelometry.
FormulationLyophilized from sterile PBS, PH 7.4
StorageStore at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

OVA-Hydrochlorothiazide(DCT)

Cat No.GMP-SMT-207-Ag02
Product NameOVA-Hydrochlorothiazide(DCT)
TargetHydrochlorothiazide(DCT)
Expression platformSynthetic
Bioactivity validationHydrochlorothiazide(DCT) antibodies binding, Immunogen in Sandwich Elisa, lateral-flow tests, and other immunoassays as control material in DCT level test of Cardiovascular disease (high blood pressure) and related syndrome evaluation
Products descriptionCompetitive immunoassay-validated hapten-carrier conjugates BSA-Hydrochlorothiazide(DCT) / OVA-Hydrochlorothiazide(DCT) is Synthetic.
PurityHigh (TBD)
ApplicationCompetitive immunoassay validation (Competitive ELISA), ELISA, Lateral flow immunoassay (LFIA),colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA),turbidimetric inhibition immuno assay (TINIA) and Immunonephelometry.
FormulationLyophilized from sterile PBS, PH 7.4
StorageStore at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Anti-human Hydrochlorothiazide(DCT) mouse monoclonal antibody (mAb)

Cat No.GMP-SMT-207-Ab01
Product NameAnti-human Hydrochlorothiazide(DCT) mouse monoclonal antibody (mAb)
TargetHydrochlorothiazide(DCT)
Expression platformhybridoma
IsotypesMouse IgG
Bioactivity validationHydrochlorothiazide(DCT) antigen binding, ELISA validated as capture antibody and detection antibody. Pair recommendation with other Hydrochlorothiazide(DCT) antibodies in DCT level test of Cardiovascular disease (high blood pressure) and related syndrome evaluation.
TagmFc
Products descriptionAnti-human Hydrochlorothiazide(DCT) mouse monoclonal antibody (mAb) is a mouse monoclonal antibody produced by hybridoma technology.
PurityHigh (TBD)
ApplicationCompetitive immunoassay validation (Competitive ELISA), ELISA, Lateral flow immunoassay (LFIA), colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA), turbidimetric inhibition immuno assay (TINIA) and Immunonephelometry.
FormulationLyophilized from sterile PBS, PH 7.4
StorageStore at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Anti-human Hydrochlorothiazide(DCT) human monoclonal antibody (mAb)

Cat No.GMP-SMT-207-Ab02
Product NameAnti-human Hydrochlorothiazide(DCT) human monoclonal antibody (mAb)
TargetHydrochlorothiazide(DCT)
Expression platformhybridoma
IsotypesHuman IgG1
Bioactivity validationHydrochlorothiazide(DCT) antigen binding, ELISA validated as capture antibody and detection antibody. Pair recommendation with other Hydrochlorothiazide(DCT) antibodies in DCT level test of Cardiovascular disease (high blood pressure) and related syndrome evaluation.
TaghFc
Products descriptionAnti-human Hydrochlorothiazide(DCT) mouse monoclonal antibody (mAb) is a human monoclonal antibody produced by CHO.
PurityPurity: ≥95% (SDS-PAGE)
ApplicationCompetitive immunoassay validation (Competitive ELISA), ELISA, Lateral flow immunoassay (LFIA), colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA), turbidimetric inhibition immuno assay (TINIA) and Immunonephelometry.
FormulationSupplied as a 0.2 μM filtered solution of PBS, PH7.4.
StorageStore at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.


Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Target/Biomarker information


    1. What is Hydrochlorothiazide, and What Role Does it Play in In Vitro Diagnosis (IVD)?

    Hydrochlorothiazide (HCTZ) is a widely used pharmaceutical compound classified as a thiazide diuretic. Thiazide diuretics are medications that promote diuresis, or the elimination of excess salt and water from the body through urine. In the context of in vitro diagnosis (IVD), Hydrochlorothiazide holds a pivotal position as an analyte with significant clinical implications, especially in the management of hypertension (high blood pressure).

    Role in IVD:

    Hypertension Management: Hypertension, or high blood pressure, is a prevalent and critical health condition affecting millions worldwide. Hydrochlorothiazide is a mainstay medication in the treatment and management of hypertension. Within the realm of IVD, various assays and tests are employed to quantify Hydrochlorothiazide levels in biological samples, such as blood or urine. These measurements serve a crucial role in monitoring the response of hypertensive patients to treatment.

    Treatment Efficacy Assessment: The quantification of Hydrochlorothiazide through IVD tests is essential for assessing the effectiveness of hypertension treatment. These tests allow healthcare professionals to monitor changes in drug levels over time, providing insights into how well the medication is controlling blood pressure.

    Dosing Optimization: Precise and individualized dosing of medications is a cornerstone of effective hypertension management. IVD procedures help optimize Hydrochlorothiazide dosages. By assessing drug concentrations, healthcare providers can fine-tune treatment plans, ensuring that patients receive the most suitable and effective doses tailored to their unique needs.

    2. Why Measure Hydrochlorothiazide?

    Measuring Hydrochlorothiazide is instrumental for several key reasons:

    Treatment Evaluation: IVD assays for Hydrochlorothiazide are indispensable for evaluating the success of hypertension treatment. By quantifying the drug in patient samples, healthcare practitioners can gauge the therapeutic response and make informed decisions regarding treatment adjustments. This ongoing evaluation is crucial for maintaining blood pressure within a healthy range and preventing complications associated with hypertension.

    Patient Adherence Assessment: Monitoring Hydrochlorothiazide levels through IVD aids in the assessment of patient adherence to prescribed regimens. Deviations in drug concentrations may suggest non-compliance, prompting healthcare professionals to engage patients in discussions about medication adherence. This fosters open communication between patients and providers, ensuring that treatment plans are followed as prescribed.

    Side Effect Prevention: While Hydrochlorothiazide is an effective antihypertensive medication, it can potentially lead to side effects, particularly if dosage levels are inappropriate. IVD measurements help mitigate these risks by ensuring that patients remain within the therapeutic range, minimizing the likelihood of adverse reactions. This proactive approach promotes patient safety and well-being.

    Individualized Care: The era of personalized medicine emphasizes tailoring treatment strategies to the unique needs of each patient. IVD assays for Hydrochlorothiazide facilitate this approach by allowing healthcare providers to analyze drug levels in individual patients. This not only optimizes blood pressure management but also enhances overall therapeutic outcomes.

    In conclusion, the precise measurement of Hydrochlorothiazide through IVD procedures is indispensable for evaluating treatment efficacy, ensuring patient compliance, preventing adverse effects, and delivering individualized care to individuals dealing with hypertension. This approach enhances the quality of healthcare and contributes to improved patient outcomes in the management of high blood pressure and associated conditions. By combining pharmacological insights with advanced diagnostic tools, healthcare professionals can provide more effective and patient-centric hypertension management.



    About GDU


    GDU

    GDU helps global diagnostic partners in high quality of raw material discovery, development, and application. GDU believes in Protein&antibody Innovation for more reliable diagnostic solutions.